SBH
CTKB icon

Segall Bryant & Hamill’s Cytek Biosciences CTKB Stock Holding History

Segall Bryant & Hamill’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,501
Closed -$367K – 589
2024
Q4 		$367K Buy
+56,501
New +$337K 0.01% 561

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Segall Bryant & Hamill's CTKB Position: Q1 2025 in Review

Segall Bryant & Hamill sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 56,501 shares — an estimated $367K sold.

Segall Bryant & Hamill first reported a position in CTKB in Q4 2024 and held it in 1 quarter. The position peaked at $367K in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

  • Segall Bryant & Hamill reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 56,501 Cytek Biosciences shares in Q1 2025, an estimated $367K.
  • Segall Bryant & Hamill first reported a position in Cytek Biosciences in Q4 2024 and held it in 1 quarter.
  • Segall Bryant & Hamill's Cytek Biosciences position peaked at $367K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Segall Bryant & Hamill's 13F filing for Q1 2025, filed 2 May 2025.